Highest-materiality recent filing
Jury found for Cytek on 3 of 4 asserted claims (noninfringement and invalidity).
Cytek Biosciences Q2 2026 revenue $48.1M (+6% YoY); net loss widens to $12.2M from $5.6M
Total revenue $48.1M, up 6% YoY; GAAP gross margin improved to 59% from 52%.
Cytek Q1 revenue $44.1M (+6% YoY); net loss widens to $18.9M; reaffirms FY guidance
Total revenue $44.1M (+6% YoY); service revenue $15.4M (+15%).
Cytek Q4 revenue $62.1M (+8% YoY); net loss $44.1M on $38.1M deferred tax valuation allowance
Full-year 2025 revenue $201.5M (+1% YoY); Q4 set record quarterly revenue.
Cytek sees Q4 rev $62M (+8% YoY); FY2025 rev ~$201M
Preliminary Q4 2025 revenue of ~$62M, up 8% YoY and 19% QoQ.
Cytek Q3 2025 net loss $5.5M; adjusted EBITDA $2.5M; revenue +2% to $52.3M
Total revenue $52.3M, +2% YoY; installed base 3,456 instruments (+161 units in Q3).
Cytek Q2 2025 revenue $45.6M (-2% YoY); narrows 2025 guidance to $196-205M
Revenue $45.6M, down 2% YoY; net loss $5.6M vs $10.4M loss in Q2 2024.
Cytek Q1 revenue down 7.6% to $41.5M; net loss widens; FY2025 guidance reduced
Revenue $41.5M (-7.6% YoY); gross margin 49% vs 51%; net loss $11.4M vs $6.2M loss prior year.
Cytek Biosciences Q4 rev $57.5M (-1.3%); FY24 net loss $6.0M; guides FY25 rev $204-212M
Full year 2024 revenue $200.5M (+3.9% YoY); Q4 revenue $57.5M (-1.3% YoY, +1.4% constant currency).
Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago
Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.
Cytek Q2 revenue $46.6M, -6% YoY; net loss widens to $10.4M
Revenue $46.6M (-6% YoY, +4% QoQ); GAAP gross margin 55% (adjusted 58%).
Cytek Q1 revenue $44.9M (+21% YoY); organic revenue up 11%; reaffirms 2024 guidance
Total revenue $44.9M, +21% YoY; organic revenue (ex-Luminex) $37.3M, +11%.
Cytek Biosciences appoints William McCombe as CFO, reaffirms 2024 revenue guidance
Patrik Jeanmonod steps down as CFO to become Head of Corporate Development Analytics, effective March 17, 2024.
Total revenue Q4 $58.6M (+21% YoY); organic $48.8M (+1%); full year $193.4M (+18%).
Cytek Biosciences prelim FY2023 revenue near high end of $188M-$192M guidance
Preliminary full-year 2023 revenue expected near high end of prior guidance range of $188M-$192M.
Cytek Q3 revenue $48M (+19%), organic growth 2%; net loss $6.5M; FY guidance $188-192M
Total revenue $48.0M (+19% YoY); organic revenue $41.2M (+2%); acquired Luminex contributed $6.8M.
Cytek Q2 revenue up 24% to $49.7M; net loss widens to $4.4M
Revenue $49.7M (+24% YoY); organic revenue $41.5M (+3%) excl. $8.2M from Luminex acquisition.
Cytek acquired flow cytometry business with $43.1M revenue, $4.4M loss in 2022
Purchase price was $46.5M less $1.6M working capital adjustments and transaction fees.
Total revenue $37.1M, up 6% YoY; constant-currency revenue $38.1M (+9%).
Cytek Q4 revenue $48.3M (+24% YoY); guides FY2023 $225-235M (+37-43%)
Full-year 2022 revenue $164.0M, up 28% YoY (34% constant currency); net income $2.5M.
Cytek Biosciences to acquire flow cytometry & imaging assets from Luminex for $46.5M
Purchase price ~$46.5M cash; deal expected to close within 30 days; includes >7,000 installed instruments.
Cytek Q3 revenue $40.5M (+18% YoY); net income $1.6M; guides FY near high end of $160-168M
Revenue $40.5M (+18% YoY); gross margin improved to 66.4% from 61.9%.
Cytek Biosciences appoints Chris Williams as COO, effective Oct. 31, 2022
Chris Williams appointed COO, reporting to CEO Wenbin Jiang; focused on scaling global operations.
Cytek Q2 revenue $40.2M (+32% YoY); net loss of $0.7M vs prior-year net income $2.7M
Revenue $40.2M, up 32% YoY; gross profit $24.6M (61% margin) vs $19.7M (65% margin) prior year.
Cytek Q1 revenue up 44% to $35.1M; raises FY2022 revenue guidance
Revenue $35.1M, +44% YoY; installed base grew to 1,226 instruments with 116 new placements.
Cytek Q4 revenue $38.9M (+27% YoY); FY2021 revenue $128M (+38%); guides FY2022 $160-168M
Q4 2021 revenue $38.9M (+27% YoY); FY2021 revenue $128.0M (+38% YoY).
Cytek Q3 revenue $34.4M (+37% YoY); net income $1.6M down from $6.5M
Total revenue $34.4M, up 37% YoY; gross margin 62% (non-GAAP 64%).
Cytek Biosciences Q2 revenue $30.4M (+59% YoY); operating income turns positive at $3.8M
Revenue $30.4M, +59% YoY; gross margin improved to 65% from 43%.
Cytek Biosciences closes IPO of 14.56M shares at $17.00 per share, raising $200M gross
Closed IPO on July 27, 2021; issued 14,564,635 shares at $17.00 per share.
On May 27, 2026, Philippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc. (the “Company”), effective as of June 5, 2026, to pursue another career opportunity.
On September 9, 2024, Paul Christopher Williams submitted his resignation from his position as the Chief Operating Officer of Cytek Biosciences, Inc. (the “Company”), effective as of September 27, 2024, to pursue another career opportunity.
Effective as of March 17, 2024, Patrik Jeanmonod stepped down from his position as the Chief Financial Officer of Cytek Biosciences, Inc. (the “Company”) to serve as the Company’s Head of Corporate Development Analytics.
On March 19, 2024, the Board of Directors of the Company announced the appointment of William (“Bill”) McCombe as the Chief Financial Officer of the Company, effective March 18, 2024.
the Board of Directors (the “Board”) of Cytek Biosciences, Inc. (the “Company”) announced the appointment of Chris Williams as the Company’s Chief Operating Officer, effective October 31, 2022.
the Board unanimously voted to (i) increase the number of authorized directors on the Board from six to seven and (ii) appoint Dr. Vera Imper to serve as a Class II director of the Company, effective December 31, 2021
Max materiality 0.85 · Median 0.65 · Most common event earnings